Logo image of ELDN

ELEDON PHARMACEUTICALS INC (ELDN) Stock Fundamental Analysis

USA - NASDAQ:ELDN - US28617K1016 - Common Stock

1.76 USD
-0.13 (-6.88%)
Last: 11/13/2025, 8:00:02 PM
1.7225 USD
-0.04 (-2.13%)
After Hours: 11/13/2025, 8:00:02 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ELDN. ELDN was compared to 531 industry peers in the Biotechnology industry. ELDN has a great financial health rating, but its profitability evaluates not so good. ELDN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ELDN had positive earnings in the past year.
ELDN had a negative operating cash flow in the past year.
ELDN had negative earnings in each of the past 5 years.
ELDN had a negative operating cash flow in each of the past 5 years.
ELDN Yearly Net Income VS EBIT VS OCF VS FCFELDN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

ELDN has a Return On Assets of -7.12%. This is amongst the best in the industry. ELDN outperforms 86.44% of its industry peers.
Looking at the Return On Equity, with a value of -9.73%, ELDN belongs to the top of the industry, outperforming 88.32% of the companies in the same industry.
Industry RankSector Rank
ROA -7.12%
ROE -9.73%
ROIC N/A
ROA(3y)-82.01%
ROA(5y)-55.57%
ROE(3y)-91.6%
ROE(5y)-61.56%
ROIC(3y)N/A
ROIC(5y)N/A
ELDN Yearly ROA, ROE, ROICELDN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ELDN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ELDN Yearly Profit, Operating, Gross MarginsELDN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, ELDN has more shares outstanding
ELDN has more shares outstanding than it did 5 years ago.
There is no outstanding debt for ELDN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ELDN Yearly Shares OutstandingELDN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ELDN Yearly Total Debt VS Total AssetsELDN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -3.05, we must say that ELDN is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -3.05, ELDN is in line with its industry, outperforming 46.52% of the companies in the same industry.
ELDN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.05
ROIC/WACCN/A
WACCN/A
ELDN Yearly LT Debt VS Equity VS FCFELDN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

ELDN has a Current Ratio of 8.12. This indicates that ELDN is financially healthy and has no problem in meeting its short term obligations.
ELDN has a Current ratio of 8.12. This is in the better half of the industry: ELDN outperforms 74.58% of its industry peers.
ELDN has a Quick Ratio of 8.12. This indicates that ELDN is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ELDN (8.12) is better than 74.76% of its industry peers.
Industry RankSector Rank
Current Ratio 8.12
Quick Ratio 8.12
ELDN Yearly Current Assets VS Current LiabilitesELDN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

1

3. Growth

3.1 Past

ELDN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 106.86%, which is quite impressive.
EPS 1Y (TTM)106.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 6.10% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y17.57%
EPS Next 2Y-1.47%
EPS Next 3Y-1.61%
EPS Next 5Y6.1%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ELDN Yearly Revenue VS EstimatesELDN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 50M 100M 150M 200M
ELDN Yearly EPS VS EstimatesELDN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 -100 -200 -300 -400 -500

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 12.57, the valuation of ELDN can be described as correct.
Based on the Price/Earnings ratio, ELDN is valued cheaper than 96.42% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 25.91. ELDN is valued rather cheaply when compared to this.
ELDN is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 12.57
Fwd PE N/A
ELDN Price Earnings VS Forward Price EarningsELDN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ELDN Per share dataELDN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.72
PEG (5Y)N/A
EPS Next 2Y-1.47%
EPS Next 3Y-1.61%

More info and screens

0

5. Dividend

5.1 Amount

ELDN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ELEDON PHARMACEUTICALS INC

NASDAQ:ELDN (11/13/2025, 8:00:02 PM)

After market: 1.7225 -0.04 (-2.13%)

1.76

-0.13 (-6.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06
Earnings (Next)03-18 2026-03-18/amc
Inst Owners67.44%
Inst Owner Change-0.17%
Ins Owners0.03%
Ins Owner Change0%
Market Cap105.39M
Revenue(TTM)N/A
Net Income(TTM)-10.31M
Analysts84.62
Price Target9.79 (456.25%)
Short Float %5.96%
Short Ratio3.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)59.36%
Min EPS beat(2)44.59%
Max EPS beat(2)74.14%
EPS beat(4)4
Avg EPS beat(4)106.42%
Min EPS beat(4)0.4%
Max EPS beat(4)306.56%
EPS beat(8)7
Avg EPS beat(8)30.62%
EPS beat(12)9
Avg EPS beat(12)19.58%
EPS beat(16)12
Avg EPS beat(16)16.71%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.13%
EPS NY rev (1m)0%
EPS NY rev (3m)5.45%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 12.57
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.99
P/tB 1.43
EV/EBITDA N/A
EPS(TTM)0.14
EY7.95%
EPS(NY)-1.08
Fwd EYN/A
FCF(TTM)-1.08
FCFYN/A
OCF(TTM)-1.08
OCFYN/A
SpS0
BVpS1.77
TBVpS1.23
PEG (NY)0.72
PEG (5Y)N/A
Graham Number2.36
Profitability
Industry RankSector Rank
ROA -7.12%
ROE -9.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-82.01%
ROA(5y)-55.57%
ROE(3y)-91.6%
ROE(5y)-61.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.12
Quick Ratio 8.12
Altman-Z -3.05
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)106.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.74%
EPS Next Y17.57%
EPS Next 2Y-1.47%
EPS Next 3Y-1.61%
EPS Next 5Y6.1%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-52.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-100.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-100.4%
OCF growth 3YN/A
OCF growth 5YN/A

ELEDON PHARMACEUTICALS INC / ELDN FAQ

What is the fundamental rating for ELDN stock?

ChartMill assigns a fundamental rating of 3 / 10 to ELDN.


What is the valuation status of ELEDON PHARMACEUTICALS INC (ELDN) stock?

ChartMill assigns a valuation rating of 3 / 10 to ELEDON PHARMACEUTICALS INC (ELDN). This can be considered as Overvalued.


How profitable is ELEDON PHARMACEUTICALS INC (ELDN) stock?

ELEDON PHARMACEUTICALS INC (ELDN) has a profitability rating of 2 / 10.


Can you provide the expected EPS growth for ELDN stock?

The Earnings per Share (EPS) of ELEDON PHARMACEUTICALS INC (ELDN) is expected to grow by 17.57% in the next year.